title: Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir.
abstract: Greater understanding of the hepatitis C virus (HCV) genome and life cycle of the HCV virion allows for new targets for therapy that directly act on the viral machinery to inhibit replication. Numerous direct-acting antivirals are in development, and four have been brought to market. Simeprevir, a second-generation protease inhibitor, has been approved for HCV genotype 1 patients in combination with pegylated interferon-α and ribavirin. Sofosbuvir, a novel nucleotide analog, has pangenotypic coverage and has been approved for HCV genotype 1 patients with ribavirin and pegylated interferon-α. For HCV genotypes 2 and 3, an all-oral regimen of sofosbuvir with ribavirin has become the new gold standard for treatment. The efficacy and safety for these two novel therapies among various subpopulations of those infected with chronic hepatitis C are discussed in the following review. In addition, off-label and future therapeutic regimens are addressed, as well as the concerns about cost of current and future therapies.
authors.affiliation: Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago Hospitals, Chicago, IL, USA.
authors.forename: John N
authors.initials: JN
authors.lastname: Gaetano
keywords: HCV genotype; liver disease; treatment-naïve and treatment experienced
references.citation: N Engl J Med. 2014 Jan 16;370(3):222-32
references.pmid: 24428468
references.citation: Lancet. 2013 Jun 15;381(9883):2100-7
references.pmid: 23499440
references.citation: N Engl J Med. 2011 Jun 23;364(25):2405-16
references.pmid: 21696307
references.citation: Nat Struct Biol. 1999 Oct;6(10):937-43
references.pmid: 10504728
references.citation: N Engl J Med. 2013 May 16;368(20):1859-61
references.pmid: 23675657
references.citation: N Engl J Med. 2013 May 16;368(20):1878-87
references.pmid: 23607594
references.citation: J Mol Biol. 2006 Apr 7;357(4):1051-7
references.pmid: 16476448
references.citation: N Engl J Med. 2011 Mar 31;364(13):1195-206
references.pmid: 21449783
references.citation: Curr Gastroenterol Rep. 2013 Jan;15(1):305
references.pmid: 23269576
references.citation: Gastroenterology. 2013 Aug;145(2):375-82.e1-2
references.pmid: 23583430
references.citation: Hepatology. 2012 Jan;55(1):307-15
references.pmid: 22105599
references.citation: Liver Int. 2011 Sep;31(8):1090-101
references.pmid: 21745274
references.citation: Antimicrob Agents Chemother. 2008 Dec;52(12):4356-69
references.pmid: 18838588
references.citation: Curr Opin Virol. 2013 Oct;3(5):514-20
references.pmid: 23896281
references.citation: Hepatology. 2013 Dec;58(6):1918-29
references.pmid: 23907700
references.citation: Lancet. 2014 Feb 8;383(9916):515-23
references.pmid: 24209977
references.citation: J Mol Biol. 2006 Aug 4;361(1):33-45
references.pmid: 16828488
references.citation: JAMA. 2013 Aug 28;310(8):804-11
references.pmid: 23982366
references.citation: Viruses. 2010 Oct;2(10):2169-95
references.pmid: 21994615
references.citation: N Engl J Med. 2014 Jan 16;370(3):211-21
references.pmid: 24428467
references.citation: N Engl J Med. 2011 Mar 31;364(13):1207-17
references.pmid: 21449784
references.citation: N Engl J Med. 2013 May 16;368(20):1867-77
references.pmid: 23607593
references.citation: Lancet Infect Dis. 2013 May;13(5):401-8
references.pmid: 23499158
references.citation: Hepatology. 2014 Apr;59(4):1246-9
references.pmid: 24493069